ALNY

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Alnylam Pharmaceuticals Inc

NASDAQ | ALNY

451.23

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$59.61B

Market Cap

1410.09

P/E Ratio

0.32

EPS

$495.55

52 Week High

$205.87

52 Week Low

HEALTHCARE

Sector

ALNY Chart

Recent Chart
Price Action

ALNY Technicals

Tags:

ALNY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

Revenue & Profitability

Earnings Performance

ALNY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $4.2B
Total Current Assets $3.3B
Cash And Cash Equivalents At Carrying Value $966M
Cash And Short Term Investments $966M
Inventory $79M
Current Net Receivables $405M
Total Non Current Assets $945M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $1.7B
Other Current Assets $117M
Other Non Current Assets -
Total Liabilities $4.2B
Total Current Liabilities $1.2B
Current Accounts Payable $88M
Deferred Revenue -
Current Debt -
Short Term Debt $155M
Total Non Current Liabilities $3B
Capital Lease Obligations $271M
Long Term Debt $1B
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.7B
Other Current Liabilities $887M
Other Non Current Liabilities $1.7B
Total Shareholder Equity $67M
Treasury Stock -
Retained Earnings -$7.3B
Common Stock $1.3M
Common Stock Shares Outstanding $128M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$8.3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $57M
Capital Expenditures $34M
Change In Receivables -
Change In Inventory $14M
Profit Loss -
Cashflow From Investment -$117M
Cashflow From Financing $294M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$278M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $1.9B
Total Revenue $2.2B
Cost Of Revenue $323M
Costof Goods And Services Sold $323M
Operating Income -$177M
Selling General And Administrative $976M
Research And Development $1.1B
Operating Expenses $2.1B
Investment Income Net -
Net Interest Income -$20M
Interest Income $122M
Interest Expense $142M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $57M
Income Before Tax -$377M
Income Tax Expense -$99M
Interest And Debt Expense -
Net Income From Continuing Operations -$278M
Comprehensive Income Net Of Tax -
Ebit -$236M
Ebitda -$179M
Net Income -$278M

ALNY News

ALNY Profile

Alnylam Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Alnylam Pharmaceuticals, Inc. is a pioneering biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development and commercialization of transformative RNA interference (RNAi) therapeutics aimed at addressing genetic diseases. The company boasts a robust pipeline of innovative RNAi-based therapies and has made significant strides in the market, including the successful launch of its first commercial product. With a steadfast commitment to scientific excellence and the advancement of medicine, Alnylam is positioned as a leader in the biopharmaceutical sector, striving to redefine treatment paradigms for both rare and prevalent diseases.

LPTX
+368.57%
$2.05
DRCT
+10.93%
$0.12
QTTB
+99.54%
$4.37
KALA
+86.31%
$1.80
PAVS
-90.66%
$0.09
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
NVDA
+1.59%
$179.83
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
AXDX
-61.36%
$0.03
FTEL
+54.11%
$1.31
IVP
+2.98%
$0.12
ASST
-6.25%
$1.05
ADAP
-15.14%
$0.05
BITF
-6.75%
$3.24
PLUG
+1.51%
$2.01
CHR
+4.09%
$0.04
SOND
-23.45%
$0.12
BURU
-4.62%
$0.23
INTC
-1.56%
$39.92
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
NFE
+18.70%
$1.44
SRM
+53.27%
$10.30
TLRY
-4.69%
$0.77
AHMA
+157.58%
$12.39
BMNR
-11.98%
$29.15
CNEY
-15.81%
$1.22
RPGL
+2.39%
$0.41
BMNU
-24.74%
$6.16
IRBT
+15.18%
$1.81
NIO
-5.90%
$5.17
WULF
+4.51%
$15.51
ONDS
-3.10%
$7.65
TSLA
-0.28%
$428.92
YGMZ
+0.17%
$0.11
WLGS
-5.57%
$0.04
CLSK
-4.07%
$14.48
BYND
+2.87%
$1.01
MTSR
-0.35%
$70.50
SOFI
-1.05%
$29.40
SNAP
-0.60%
$7.63
ADTX
+21.01%
$3.80
INHD
-16.59%
$0.18
MARA
-6.26%
$11.07
PFE
-1.24%
$25.41
AFMD
-34.94%
$0.18
AAL
-0.08%
$14.03
F
+0.11%
$13.29
AMZN
+1.77%
$233.22
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
MSTR
-10.92%
$157.83
GRYP
-10.38%
$1.38
PRPH
-19.10%
$0.16
CAN
-6.65%
$0.94
MODV
-25.22%
$0.43
NCT
-29.38%
$0.54
BTBT
-7.14%
$2.20
BTG
-0.54%
$4.59
RIVN
+2.72%
$17.32
CIFR
-5.28%
$19.27
DNN
+0.03%
$2.56
AMD
+0.47%
$218.57
T
+0.77%
$26.02
HOOD
-5.73%
$121.12
RUBI
-12.21%
$0.14
PLTR
-0.09%
$168.29
VHAI
-25.00%
$0.00
GOOGL
-0.82%
$317.54
ACHR
-3.72%
$7.50
EXK
-4.32%
$9.50
RIG
+0.22%
$4.42
SAND
-6.04%
$12.12
MSFT
+1.34%
$492.01
SHOT
-74.37%
$0.39
ORCL
-1.46%
$201.95
ZAPP
-46.30%
$0.15
WBUY
+46.66%
$2.31
IBRX
-1.26%
$2.33
DVLT
-4.17%
$1.94
RGTI
-7.45%
$23.66
ITUB
-1.08%
$7.71
BBD
-1.21%
$3.65
CPNG
-4.79%
$26.81
GPUS
-7.34%
$0.28
MU
+2.70%
$236.48
GRAB
-2.44%
$5.31
PLTD
+0.21%
$7.05
CRWV
+3.17%
$75.44
AAPL
+0.30%
$279.71
IREN
-2.39%
$46.66
APLD
+3.21%
$27.97
DEFT
-12.82%
$1.32
TE
+9.58%
$4.51
HBAN
+1.47%
$16.54
AMZE
+2.47%
$0.49
HL
+2.43%
$17.23
LPTX
+368.57%
$2.05
DRCT
+10.93%
$0.12
QTTB
+99.54%
$4.37
KALA
+86.31%
$1.80
PAVS
-90.66%
$0.09
HBI
-1.82%
$6.47
VINE
+21.21%
$0.48
NVDA
+1.59%
$179.83
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
AXDX
-61.36%
$0.03
FTEL
+54.11%
$1.31
IVP
+2.98%
$0.12
ASST
-6.25%
$1.05
ADAP
-15.14%
$0.05
BITF
-6.75%
$3.24
PLUG
+1.51%
$2.01
CHR
+4.09%
$0.04
SOND
-23.45%
$0.12
BURU
-4.62%
$0.23
INTC
-1.56%
$39.92
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
NFE
+18.70%
$1.44
SRM
+53.27%
$10.30
TLRY
-4.69%
$0.77
AHMA
+157.58%
$12.39
BMNR
-11.98%
$29.15
CNEY
-15.81%
$1.22
RPGL
+2.39%
$0.41
BMNU
-24.74%
$6.16
IRBT
+15.18%
$1.81
NIO
-5.90%
$5.17
WULF
+4.51%
$15.51
ONDS
-3.10%
$7.65
TSLA
-0.28%
$428.92
YGMZ
+0.17%
$0.11
WLGS
-5.57%
$0.04
CLSK
-4.07%
$14.48
BYND
+2.87%
$1.01
MTSR
-0.35%
$70.50
SOFI
-1.05%
$29.40
SNAP
-0.60%
$7.63
ADTX
+21.01%
$3.80
INHD
-16.59%
$0.18
MARA
-6.26%
$11.07
PFE
-1.24%
$25.41
AFMD
-34.94%
$0.18
AAL
-0.08%
$14.03
F
+0.11%
$13.29
AMZN
+1.77%
$233.22
NWTN
-9.09%
$0.70
AG
+12.73%
$15.23
MSTR
-10.92%
$157.83
GRYP
-10.38%
$1.38
PRPH
-19.10%
$0.16
CAN
-6.65%
$0.94
MODV
-25.22%
$0.43
NCT
-29.38%
$0.54
BTBT
-7.14%
$2.20
BTG
-0.54%
$4.59
RIVN
+2.72%
$17.32
CIFR
-5.28%
$19.27
DNN
+0.03%
$2.56
AMD
+0.47%
$218.57
T
+0.77%
$26.02
HOOD
-5.73%
$121.12
RUBI
-12.21%
$0.14
PLTR
-0.09%
$168.29
VHAI
-25.00%
$0.00
GOOGL
-0.82%
$317.54
ACHR
-3.72%
$7.50
EXK
-4.32%
$9.50
RIG
+0.22%
$4.42
SAND
-6.04%
$12.12
MSFT
+1.34%
$492.01
SHOT
-74.37%
$0.39
ORCL
-1.46%
$201.95
ZAPP
-46.30%
$0.15
WBUY
+46.66%
$2.31
IBRX
-1.26%
$2.33
DVLT
-4.17%
$1.94
RGTI
-7.45%
$23.66
ITUB
-1.08%
$7.71
BBD
-1.21%
$3.65
CPNG
-4.79%
$26.81
GPUS
-7.34%
$0.28
MU
+2.70%
$236.48
GRAB
-2.44%
$5.31
PLTD
+0.21%
$7.05
CRWV
+3.17%
$75.44
AAPL
+0.30%
$279.71
IREN
-2.39%
$46.66
APLD
+3.21%
$27.97
DEFT
-12.82%
$1.32
TE
+9.58%
$4.51
HBAN
+1.47%
$16.54
AMZE
+2.47%
$0.49
HL
+2.43%
$17.23
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.